Business Update
07 déc. 2023 07h00 HE
|
Oxford BioMedica plc
Business Update Current contracted value signed in 2023 of £124 million, an increase of 47% compared to £85 million in the year ending 31 December 2022 (excluding COVID-19 vaccine manufacturing)On...
Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO
04 déc. 2023 07h04 HE
|
Oxford BioMedica plc
Oxford Biomedica signs agreement to acquire ABL Europe from Institut Mérieux, consolidating position as a global pure-play CDMO Oxford Biomedica announces the signing of a sale and purchase agreement...
Oxford Biomedica and Institut Mérieux enter into exclusive negotiations with respect to the proposed acquisition by Oxford Biomedica of ABL Europe from Institut Mérieux as part of pure-play CDMO transformation
20 sept. 2023 07h46 HE
|
Oxford BioMedica plc
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of...
Oxford Biomedica Plc - INTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2023
20 sept. 2023 07h41 HE
|
Oxford BioMedica plc
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of...
Oxford Biomedica to host webinar showcasing the TetraVecta™ system
07 sept. 2023 07h00 HE
|
Oxford BioMedica plc
Oxford Biomedica to host webinar showcasing the TetraVectaTM system Oxford, UK – 07 September 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led...
Oxford Biomedica launches TetraVecta - the next generation lentiviral vector system
15 mai 2023 07h00 HE
|
Oxford BioMedica plc
Oxford Biomedica launches TetraVectaTM - the next generation lentiviral vector system Oxford, UK – 15 May 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and...
Oxford Biomedica Appoints Leone Patterson as Non-Executive Director
26 avr. 2023 07h00 HE
|
Oxford BioMedica plc
Oxford Biomedica Appoints Leone Patterson as Non-Executive Director Oxford, UK – 26th April 2023: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a quality and innovation-led...
Dr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023
20 févr. 2023 07h00 HE
|
Oxford BioMedica plc
Dr Frank Mathias to join Oxford Biomedica as new CEO on 27 March 2023 Dr Mathias brings a wealth of experience in innovation, contract development and manufacturing to Oxford BiomedicaStuart...
Oxford Biomedica Appoints Dr Frank Mathias as Chief Executive Officer
22 nov. 2022 07h00 HE
|
Oxford BioMedica plc
The information contained within this announcement is deemed by the Group to constitute inside information as stipulated under the Market Abuse Regulation (EU) No. 596/2014 (as it forms part of...
Oxford Biomedica to complete sale and leaseback of Windrush Court facility for £60 million
14 nov. 2022 07h00 HE
|
Oxford BioMedica plc
Oxford Biomedica to complete sale and leaseback of Windrush Court facility for £60 million Oxford, UK – 14 November 2022: Oxford Biomedica plc (LSE:OXB) (“Oxford Biomedica” or “the Company”), a...